WO2009044553A1 - 貧血治療薬のスクリーニング方法 - Google Patents

貧血治療薬のスクリーニング方法 Download PDF

Info

Publication number
WO2009044553A1
WO2009044553A1 PCT/JP2008/002781 JP2008002781W WO2009044553A1 WO 2009044553 A1 WO2009044553 A1 WO 2009044553A1 JP 2008002781 W JP2008002781 W JP 2008002781W WO 2009044553 A1 WO2009044553 A1 WO 2009044553A1
Authority
WO
WIPO (PCT)
Prior art keywords
screening
activity
epo
dna
anemia
Prior art date
Application number
PCT/JP2008/002781
Other languages
English (en)
French (fr)
Inventor
Tatsuaki Nishiyama
Takeshi Doi
Original Assignee
Kowa Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Company, Ltd. filed Critical Kowa Company, Ltd.
Publication of WO2009044553A1 publication Critical patent/WO2009044553A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

　本発明は、ＡｈＲアゴニスト作用を有さないＥＰＯ産生亢進剤をスクリーニングする方法、及び該方法において用いられるＤＮＡを提供する。 　エリスロポエチン（ＥＰＯ）遺伝子の５´上流プロモーター配列中にあるアリルヒドロカーボン受容体（ＡｈＲ）が結合する可能性のある生体異物応答配列（Xenobiotic-responsive element、ＸＲＥ配列）に変異を加え、ＸＲＥ配列が不活化されているが、ＥＰＯのプロモーター活性は有するＤＮＡを用いることを特徴とする、ＥＰＯ遺伝子の転写を制御する作用、特に転写活性を促進する作用を有する物質のスクリーニング方法を提供する。更に、本スクリーニングで得られる物質が貧血の予防又は治療に有用な物質である。
PCT/JP2008/002781 2007-10-05 2008-10-03 貧血治療薬のスクリーニング方法 WO2009044553A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007261673 2007-10-05
JP2007-261673 2007-10-05

Publications (1)

Publication Number Publication Date
WO2009044553A1 true WO2009044553A1 (ja) 2009-04-09

Family

ID=40525985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/002781 WO2009044553A1 (ja) 2007-10-05 2008-10-03 貧血治療薬のスクリーニング方法

Country Status (1)

Country Link
WO (1) WO2009044553A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816853A (zh) * 2012-08-30 2012-12-12 山东百福基因科技有限公司 运动机能相关基因epo荧光检测试剂盒及检测方法
CN110846339A (zh) * 2019-10-18 2020-02-28 江南大学 一种提高粘质沙雷氏菌抗酸胁迫能力的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052859A1 (ja) * 2002-12-06 2004-06-24 Kowa Co., Ltd. エリスロポエチン産生促進剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052859A1 (ja) * 2002-12-06 2004-06-24 Kowa Co., Ltd. エリスロポエチン産生促進剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHAN,W.K. ET AL.: "Cross-talk between the aryl hydrocarbon receptor and hypoxia inducible factor signaling pathways. Demonstration of competition and compensation.", J BIOL CHEM., vol. 274, no. 17, 23 April 1999 (1999-04-23), pages 12115 - 12123 *
DENISON,M.S. ET AL.: "The DNA recognition site for the dioxin-Ah receptor complex. Nucleotide sequence and functional analysis.", J BIOL CHEM., vol. 263, no. 33, 25 November 1988 (1988-11-25), pages 17221 - 17224 *
GUPTA,M. ET AL.: "The role of the near upstream sequence in hypoxia-induced expression of the erythropoietin gene.", NUCLEIC ACIDS RES. ACIDS RES., vol. 24, no. 23, 1 December 1996 (1996-12-01), pages 4768 - 4774 *
TARUMOTO,T. ET AL.: "N(G)-monomethyl-L-arginine inhibits erythropoietin gene expression by stimulating GATA-2.", BLOOD., vol. 96, no. 5, 1 September 2000 (2000-09-01), pages 1716 - 1722 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816853A (zh) * 2012-08-30 2012-12-12 山东百福基因科技有限公司 运动机能相关基因epo荧光检测试剂盒及检测方法
CN110846339A (zh) * 2019-10-18 2020-02-28 江南大学 一种提高粘质沙雷氏菌抗酸胁迫能力的方法
CN110846339B (zh) * 2019-10-18 2021-06-25 江南大学 一种提高粘质沙雷氏菌抗酸胁迫能力的方法

Similar Documents

Publication Publication Date Title
WO2009045370A3 (en) Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
EP2514826A3 (en) Use of interfering RNA molecules to down regulate the expression of specific genes or family of genes
WO2007107789A3 (en) Treatment of cns conditions
IL225203A (en) An isolated complementary factor polypeptide, methods for its preparation, its uses and a factor that lowers its expression or activity
EP3586868A3 (en) Liver-specific nucleic acid regulatory elements and methods and use thereof
EP2218785A3 (en) Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
WO2007041610A3 (en) Genes and proteins associated with angiogenesis and uses thereof
WO2010045258A3 (en) Spirocyclic gpr40 modulators
WO2007106236A3 (en) Pyrrolo-pyridine kinase modulators
WO2008062276A3 (en) Acetylene derivatives as stearoyl coa desaturase inhibitors
PT1913001E (pt) (r)-n-metilnaltrexona, processos para a sua síntese e sua utilização farmacêutica
DK1725672T3 (da) Fremgangsmåde til fremstilling af L-lysin under anvendelse af coryneforme bakterier
WO2007115205A3 (en) Improved methods, systems and compositions for monitoring enzyme activity and applications thereof
WO2005059097A3 (en) Methods for high fidelity production of long nucleic acid molecules
ATE380184T1 (de) Derivate von alkylpiperazin- und alkylhomopiperazincarboxylaten, verfahren zu deren herstellung und deren verwendung als inhibitoren des faah-enzyms
EA015496B9 (ru) Бифенилкарбоксамиды
EP2280010A3 (en) Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
MX350510B (es) Aminación (r)-selectiva.
WO2008024304A3 (en) Compounds for treatment of proliferative disorders
WO2011044437A3 (en) Polony sequencing methods
GB2450840A (en) Screening Systems Utilizing RTP801
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
AU2016204334A1 (en) Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2006061215A3 (de) 2-alkyl-cycloalk(en)yl-carboxamide
WO2009044383A8 (en) Nucleic acid codifying for a utrophin transcription specific regulating protein, protein codified thereby and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08836033

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 08836033

Country of ref document: EP

Kind code of ref document: A1